Q1 EPS Estimates for Legend Biotech Raised by HC Wainwright

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) – Investment analysts at HC Wainwright lifted their Q1 2026 earnings estimates for Legend Biotech in a research report issued to clients and investors on Wednesday, April 15th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of $0.00 for the quarter, up from their prior estimate of ($0.04). HC Wainwright currently has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Legend Biotech’s Q4 2026 earnings at $0.11 EPS, FY2026 earnings at $0.21 EPS, Q3 2027 earnings at $0.30 EPS and FY2027 earnings at $1.14 EPS.

Legend Biotech (NASDAQ:LEGN) last posted its quarterly earnings data on Wednesday, March 11th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.18. The company had revenue of $306.30 million for the quarter, compared to the consensus estimate of $310.21 million. Legend Biotech had a negative net margin of 28.86% and a negative return on equity of 21.93%. The firm’s revenue was up 64.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.07 earnings per share.

A number of other equities analysts also recently issued reports on LEGN. Rothschild & Co Redburn downgraded shares of Legend Biotech from a “buy” rating to a “neutral” rating and set a $24.00 price objective on the stock. in a report on Thursday, February 12th. Jefferies Financial Group reissued a “buy” rating and issued a $69.00 price objective on shares of Legend Biotech in a report on Tuesday, March 10th. Oppenheimer assumed coverage on shares of Legend Biotech in a report on Wednesday, January 7th. They issued an “outperform” rating and a $75.00 price objective on the stock. Morgan Stanley dropped their price objective on shares of Legend Biotech from $50.00 to $49.00 and set an “overweight” rating on the stock in a report on Wednesday, March 11th. Finally, Truist Financial downgraded shares of Legend Biotech from a “strong-buy” rating to a “hold” rating in a report on Friday, March 20th. Eleven analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $58.31.

Legend Biotech Trading Up 0.4%

LEGN opened at $21.17 on Friday. The company has a market cap of $3.92 billion, a price-to-earnings ratio of -26.46 and a beta of 0.08. The company’s 50 day moving average is $18.51 and its 200 day moving average is $23.53. Legend Biotech has a 12-month low of $16.24 and a 12-month high of $45.30.

Hedge Funds Weigh In On Legend Biotech

Several large investors have recently added to or reduced their stakes in the company. Clearstead Advisors LLC lifted its holdings in Legend Biotech by 76.5% during the third quarter. Clearstead Advisors LLC now owns 847 shares of the company’s stock valued at $28,000 after purchasing an additional 367 shares in the last quarter. Invesco Ltd. raised its position in shares of Legend Biotech by 4.4% during the fourth quarter. Invesco Ltd. now owns 13,710 shares of the company’s stock valued at $298,000 after buying an additional 581 shares during the last quarter. OFI Invest Asset Management raised its position in shares of Legend Biotech by 102.6% during the third quarter. OFI Invest Asset Management now owns 1,228 shares of the company’s stock valued at $40,000 after buying an additional 622 shares during the last quarter. Parallel Advisors LLC raised its position in shares of Legend Biotech by 171.9% during the third quarter. Parallel Advisors LLC now owns 1,047 shares of the company’s stock valued at $34,000 after buying an additional 662 shares during the last quarter. Finally, Fox Run Management L.L.C. raised its position in shares of Legend Biotech by 4.3% during the fourth quarter. Fox Run Management L.L.C. now owns 20,806 shares of the company’s stock valued at $452,000 after buying an additional 863 shares during the last quarter. Hedge funds and other institutional investors own 70.89% of the company’s stock.

Insiders Place Their Bets

In other Legend Biotech news, CEO Ying Huang sold 9,936 shares of Legend Biotech stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $8.77, for a total transaction of $87,138.72. Following the transaction, the chief executive officer owned 247,438 shares of the company’s stock, valued at $2,170,031.26. The trade was a 3.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.02% of the stock is owned by corporate insiders.

Key Legend Biotech News

Here are the key news stories impacting Legend Biotech this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and maintained a $50.00 price target on LEGN, a bullish endorsement that supports upside expectations. MarketBeat LEGN
• Positive Sentiment: The firm raised its Q1 2026 EPS view to $0.00 from ($0.04), signaling a modest near-term improvement in profitability expectations. MarketBeat LEGN
• Neutral Sentiment: Coverage commentary on Legend alongside peers appeared in The Globe and Mail — general analyst insight rather than company-specific catalysts. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: HC Wainwright sharply cut its FY2027 EPS forecast to $1.14 from $2.28, a large downward revision that reduces long-term earnings upside and could pressure the multiple investors are willing to pay. MarketBeat LEGN
• Negative Sentiment: The firm also reduced FY2026 EPS to $0.21 from $0.42, signaling weaker near-term profitability than previously expected. MarketBeat LEGN
• Negative Sentiment: Several quarterly estimates for 2026 were trimmed (Q2 to $0.03 from $0.06; Q3 to $0.07 from $0.14; Q4 to $0.11 from $0.26), suggesting HC Wainwright sees slower ramp in quarterly results — a near-term headwind for the shares. MarketBeat LEGN

About Legend Biotech

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.